Latest From Genmab AS
Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.
The company's proteasome inhibitor reduced the risk of death in combination with J&J's CD38 inhibitor in a Phase III trial. A day earlier, Amgen reported clinical holds on its Phase I MCL-1 inhibitors due to cardiac safety.
Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.
The Bill & Melinda Gates Foundation has invested $55m in an infectious disease collaboration with Germany’s BioNTech that could reach up to $100m in total funding.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Genmab AS
- Senior Management
Jan van de Winkel, PhD, Pres. & CEO
David A Eatwell, EVP, CFO
Judith Klimovsky, MD, EVP, Chief Dev. Officer
- Contact Info
Phone: (45) 7020 2728
Kalvebod Brygge 43
Copenhagen, 1560 V
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.